Moderna climbs on full FDA nod for COVID shot in children aged six months or older

** Shares of vaccine maker Moderna MRNA.O rise 3.3% to over three-months high of $33.87

** MRNA says U.S. FDA approved its COVID-19 vaccine, Spikevax, in children aged six months through 11 years who are at an increased risk of the disease

** Co expects the updated shot to be available for eligible populations in the U.S. for the 2025-26 respiratory virus season

** Piper Sandler analysts expect Moderna's COVID vaccine sales to "bottom" in 2025

** Estimate new vaccine approvals to boost product sales to $3.1 billion in 2026 and $4.5 billion in 2027

** Up to last close, stock down 21.1% YTD